IN2014CN03762A - - Google Patents

Info

Publication number
IN2014CN03762A
IN2014CN03762A IN3762CHN2014A IN2014CN03762A IN 2014CN03762 A IN2014CN03762 A IN 2014CN03762A IN 3762CHN2014 A IN3762CHN2014 A IN 3762CHN2014A IN 2014CN03762 A IN2014CN03762 A IN 2014CN03762A
Authority
IN
India
Prior art keywords
attachment
please see
please
see
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Luc Girardet
Yung-Hyo Koh
La Rosa Martha De
Esmir Gunic
Zhi Hong
Stanley Lang
Hongwoo Kim
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of IN2014CN03762A publication Critical patent/IN2014CN03762A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Road Signs Or Road Markings (AREA)
  • Pens And Brushes (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
IN3762CHN2014 2004-08-25 2005-08-25 IN2014CN03762A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60422004P 2004-08-25 2004-08-25
US60421904P 2004-08-25 2004-08-25
US68635105P 2005-05-31 2005-05-31
PCT/US2005/030259 WO2006026356A2 (en) 2004-08-25 2005-08-25 S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE

Publications (1)

Publication Number Publication Date
IN2014CN03762A true IN2014CN03762A (ko) 2015-09-25

Family

ID=36000576

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3762CHN2014 IN2014CN03762A (ko) 2004-08-25 2005-08-25

Country Status (32)

Country Link
US (8) US7947721B2 (ko)
EP (5) EP2433633A1 (ko)
JP (2) JP4952943B2 (ko)
KR (1) KR101241716B1 (ko)
CN (2) CN101083987B (ko)
AT (2) ATE528001T1 (ko)
AU (2) AU2005280130C9 (ko)
BR (2) BRPI0514630B8 (ko)
CA (1) CA2578068C (ko)
CY (2) CY1112221T1 (ko)
DK (1) DK2135608T3 (ko)
EA (2) EA014737B1 (ko)
EC (1) ECSP077322A (ko)
ES (2) ES2380604T3 (ko)
FR (1) FR16C0031I2 (ko)
HK (1) HK1133582A1 (ko)
HR (1) HRP20130075T1 (ko)
HU (1) HUS1600034I1 (ko)
IL (3) IL181523A (ko)
IN (1) IN2014CN03762A (ko)
LT (1) LTC2135608I2 (ko)
LU (1) LU93169I2 (ko)
ME (1) ME01512B (ko)
MX (1) MX2007002236A (ko)
NL (1) NL300825I2 (ko)
NZ (2) NZ553534A (ko)
PL (1) PL2135608T3 (ko)
PT (1) PT2135608E (ko)
RS (1) RS52632B (ko)
SG (2) SG185992A1 (ko)
SI (1) SI2135608T1 (ko)
WO (1) WO2006026356A2 (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
IN2014CN03762A (ko) * 2004-08-25 2015-09-25 Ardea Biosciences Inc
WO2008145562A1 (en) 2007-05-30 2008-12-04 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
EA018193B3 (ru) * 2007-11-27 2014-07-30 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CN103819419B (zh) * 2008-09-04 2016-12-07 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CA2741368A1 (en) * 2008-10-24 2010-04-29 Barry D. Quart Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio) acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010135536A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CN102040546B (zh) * 2009-10-10 2014-10-15 台州市华南医化有限公司 一种4-环丙基-1-异硫氰基萘的制备方法及中间体4-环丙基-1-萘甲醛肟/卤化物
MX2012007925A (es) * 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
US9402827B2 (en) 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (es) 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
EP2582664A4 (en) 2010-06-16 2014-07-09 Ardea Biosciences Inc PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CN101899013B (zh) * 2010-07-12 2012-07-25 山东大学 2-(2-取代芳基-2h-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用
CA2813555C (en) * 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
JP5781627B2 (ja) 2010-12-30 2015-09-24 アルデア バイオサイエンシーズ インク． ２−（５−ブロモ−４−（４−シクロプロピルナフタレン−１−イル）−４ｈ−１，２，４−トリアゾル−３−イルチオ）酢酸の多形形態およびその使用
CA2852490A1 (en) 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
WO2014198241A1 (en) * 2013-06-14 2014-12-18 Sunshine Lake Pharma Co., Ltd. Thio-1,2,4-triazole derivatives and method for preparing the same
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
US10351536B2 (en) * 2013-11-22 2019-07-16 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
CN104557748A (zh) * 2014-01-25 2015-04-29 广东东阳光药业有限公司 硫代-1,2,4-三唑衍生物的新的固体形态
CN105315218A (zh) * 2014-07-17 2016-02-10 天津药物研究院 一种制备lesinurad中间体1-萘基三唑硫酮的方法
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341361B (zh) * 2014-10-27 2017-01-11 张远强 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104311498B (zh) * 2014-10-27 2016-04-06 张远强 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (zh) * 2016-03-01 2018-05-18 山东大学 一种治疗痛风的三唑巯乙酸类化合物的制备方法
ES2931470T3 (es) 2016-06-17 2022-12-29 Medshine Discovery Inc Compuesto halogenado e isómero axialmente quiral del mismo
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
EP3372592A1 (en) 2017-03-07 2018-09-12 Zentiva, k.s. Solid forms of lesinurad amine salts
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (zh) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2019001325A1 (zh) * 2017-06-28 2019-01-03 苏州科睿思制药有限公司 雷西纳得的晶型xv及其制备方法
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
DE112022002825T5 (de) 2021-05-28 2024-03-14 Sumitomo Chemical Company, Limited Verfahren zur Herstellung von Cycloalkylbromid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US226186A (en) 1880-04-06 Car-coupling
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2006A (en) * 1841-03-16 Clamp for crimping leather
JPS5641637B2 (ko) 1973-11-26 1981-09-29
US6832996B2 (en) 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
EP0910565A1 (en) 1997-02-14 1999-04-28 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
JPH10243033A (ja) * 1997-02-28 1998-09-11 Oki Electric Ind Co Ltd 復調装置
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
ES2196898T3 (es) 1998-11-12 2003-12-16 Neurocrine Biosciences Inc Antagonistas de receptores de crf y metodos relacionados.
AU2217200A (en) 1998-12-23 2000-07-12 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
WO2000039086A1 (fr) * 1998-12-25 2000-07-06 Shionogi & Co., Ltd. Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih
US6593077B2 (en) 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
KR100638954B1 (ko) 2001-03-02 2006-10-25 스미스클라인 비참 코포레이션 역전사 효소 억제제로서의 벤조페논
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CA2484233A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
BR0313747A (pt) 2002-08-23 2005-06-21 Ribapharm Inc Inibidores de transcriptase reversa de não-nucleosìdeo
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
ES2598404T3 (es) 2003-02-07 2017-01-27 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevención de infección por el VIH
ATE500254T1 (de) 2003-09-25 2011-03-15 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7517998B2 (en) 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
IN2014CN03762A (ko) * 2004-08-25 2015-09-25 Ardea Biosciences Inc
EA018193B3 (ru) 2007-11-27 2014-07-30 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
CA2741368A1 (en) 2008-10-24 2010-04-29 Barry D. Quart Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio) acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
TWM377707U (en) 2009-09-16 2010-04-01 Nat Energy Technology Co Ltd Assembly of power supply

Also Published As

Publication number Publication date
AU2009217458A8 (en) 2009-10-29
JP2008510828A (ja) 2008-04-10
EP1789039A2 (en) 2007-05-30
AU2005280130C9 (en) 2010-03-04
LTC2135608I2 (lt) 2017-07-25
ES2374773T3 (es) 2012-02-21
MX2007002236A (es) 2007-07-09
LTPA2016024I1 (lt) 2016-09-12
US7947721B2 (en) 2011-05-24
CA2578068A1 (en) 2006-03-09
EP2135608A1 (en) 2009-12-23
ES2380604T3 (es) 2012-05-16
CY2016028I1 (el) 2016-12-14
AU2005280130B2 (en) 2009-09-10
AU2005280130C1 (en) 2010-02-18
US8252828B2 (en) 2012-08-28
EP2135608B1 (en) 2011-10-12
US8481581B2 (en) 2013-07-09
CN101083987B (zh) 2011-01-26
US20180002296A1 (en) 2018-01-04
NL300825I2 (ko) 2017-01-24
US20080176850A1 (en) 2008-07-24
BRPI0514630B1 (pt) 2020-09-15
ECSP077322A (es) 2007-04-26
DK2135608T3 (da) 2012-01-23
HRP20130075T1 (hr) 2013-02-28
BRPI0514630B8 (pt) 2021-05-25
EA200901186A1 (ru) 2010-04-30
SG155246A1 (en) 2009-09-30
US20110313157A1 (en) 2011-12-22
EA014737B1 (ru) 2011-02-28
NZ553534A (en) 2010-10-29
EP2402011A1 (en) 2012-01-04
US20100069645A1 (en) 2010-03-18
EA200700488A1 (ru) 2007-08-31
US8003681B2 (en) 2011-08-23
EA015846B1 (ru) 2011-12-30
FR16C0031I1 (ko) 2016-09-23
CN101083987A (zh) 2007-12-05
JP5457472B2 (ja) 2014-04-02
SI2135608T1 (sl) 2012-03-30
US20120283301A1 (en) 2012-11-08
IL181523A (en) 2013-12-31
IL181523A0 (en) 2007-07-04
RS52632B (en) 2013-06-28
ATE528001T1 (de) 2011-10-15
IL219131A0 (en) 2012-06-28
KR20070054694A (ko) 2007-05-29
EP2433633A1 (en) 2012-03-28
EP1789039B1 (en) 2012-01-11
US20100081827A1 (en) 2010-04-01
US20150094284A1 (en) 2015-04-02
HK1133582A1 (en) 2010-04-01
EP2135608B8 (en) 2012-03-21
CY1112221T1 (el) 2015-12-09
WO2006026356A2 (en) 2006-03-09
EP2609917A1 (en) 2013-07-03
EP1789039A4 (en) 2009-08-05
ATE540677T1 (de) 2012-01-15
WO2006026356A3 (en) 2006-08-10
PL2135608T3 (pl) 2012-07-31
CY2016028I2 (el) 2016-12-14
US8946273B2 (en) 2015-02-03
HUS1600034I1 (hu) 2016-09-28
AU2009217458A1 (en) 2009-10-15
BRPI0520870B1 (pt) 2020-11-10
US20110190491A1 (en) 2011-08-04
LU93169I2 (fr) 2016-10-10
EP2402011B1 (en) 2012-11-14
AU2009217458B2 (en) 2009-11-19
KR101241716B1 (ko) 2013-03-08
NZ581376A (en) 2011-05-27
CA2578068C (en) 2011-08-09
CN101817793B (zh) 2014-01-08
BRPI0514630A (pt) 2008-06-17
BRPI0520870B8 (pt) 2021-05-25
PT2135608E (pt) 2012-01-13
US20100267724A2 (en) 2010-10-21
ME01512B (me) 2014-04-20
SG185992A1 (en) 2012-12-28
CN101817793A (zh) 2010-09-01
JP2012077088A (ja) 2012-04-19
JP4952943B2 (ja) 2012-06-13
IL201546A (en) 2013-10-31
AU2005280130A1 (en) 2006-03-09
FR16C0031I2 (fr) 2017-03-31

Similar Documents

Publication Publication Date Title
IN2014CN03762A (ko)
IN2014CN03629A (ko)
IN2012DN02610A (ko)
SG155211A1 (en) Peptide
TWI365550B (en) Illumination source
SG149831A1 (en) Benzimidazole derivatives
ZAA200500621S (en) Earphone
GB2430762B (en) Light source arrangement
IN2014CN04215A (ko)
GB0400537D0 (en) Le beanock/the beanock
MD2731B2 (ko)
TWM259667U (en) Simple-type fixture
AU305367S (en) Shower base
GB0400945D0 (en) The bugcap
GB2411464B (en) Diffuser
CA107672S (en) Dispenser holder
HK1069723A2 (en) Faraday flashlight.
PL115148U1 (en) Chandelier
AU306341S (en) Entertainment unit
AU306760S (en) Entertainment unit
AU302487S (en) Entertainment unit
AU302484S (en) Entertainment unit
AU305007S (en) Entertainment unit
AU305697S (en) Desk
AU302525S (en) Design 1 - 5 light - lighting fixture